Alnylam Pharmaceuticals, Inc.
ALNY
$473.29
$8.361.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.24% | 5.01% | 17.21% | 22.97% | 21.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.24% | 5.01% | 17.21% | 22.97% | 21.54% |
| Cost of Revenue | 68.72% | 32.12% | 2.15% | 4.18% | 11.09% |
| Gross Profit | 50.59% | 0.96% | 20.09% | 26.81% | 23.52% |
| SG&A Expenses | 34.43% | 26.05% | 22.11% | 22.61% | 8.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.02% | 17.86% | 13.05% | 14.91% | 9.86% |
| Operating Income | 240.70% | -275.55% | 34.37% | 37.31% | 46.91% |
| Income Before Tax | 90.05% | -515.19% | -9.44% | 12.95% | 36.14% |
| Income Tax Expenses | -776.59% | -638.08% | -1,268.30% | -1,575.36% | 59.11% |
| Earnings from Continuing Operations | 113.11% | -337.46% | 18.78% | 36.82% | 34.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 113.11% | -337.46% | 18.78% | 36.82% | 34.83% |
| EBIT | 240.70% | -275.55% | 34.37% | 37.31% | 46.91% |
| EBITDA | 342.93% | -178.30% | 52.73% | 47.30% | 55.88% |
| EPS Basic | 111.86% | -330.02% | 21.16% | 38.54% | 36.38% |
| Normalized Basic EPS | 101.63% | -740.52% | -9.88% | 12.84% | 36.72% |
| EPS Diluted | 109.17% | -310.34% | 21.90% | 38.96% | 36.88% |
| Normalized Diluted EPS | 98.02% | -612.07% | -7.18% | 14.43% | 37.70% |
| Average Basic Shares Outstanding | 2.72% | 2.84% | 2.49% | 2.20% | 1.97% |
| Average Diluted Shares Outstanding | 3.88% | 1.61% | 1.25% | 0.96% | 0.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |